BLA 761169 · Regeneron Pharmaceuticals
Inmazeb
Atoltivimab, Odesivimab, Maftivimab · Injection
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Oct 14, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2) , and Clinical Studies (14) ] . INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. ( 1 ) Limitation of Use The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera . Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding whether to use INMAZEB. Limitations of Use The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding whether to use INMAZEB.
Mechanism: INMAZEB is an antiviral drug combination of three recombinant human IgG1κ monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Orthoebolavirus zairense [ see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- INMAZEB · ATOLTIVIMAB 16.7MG/1ML; ODESIVIMAB; MAFTIVIMAB · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atoltivimab" as an intervention, any sponsor and status, largest first.
- Investigational Therapeutics for the Treatment of People With Ebola Virus DiseasePivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03719586 · 681 participants · Start Nov 21, 2018 · Primary completion Sep 9, 2019
Drug: ZMapp; Remdesivir and 2 more · For: Ebola Virus
Sites: Bethesda, Maryland; Kinshasa Gombe, Democratic Republic of the Congo
- EBOla Post-Exposure ProphylaxisPivotal-lookingNot yet recruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT06841614 · 160 participants (planned) · Start Sep 2026 · Primary completion Aug 1, 2027
Drug: Ervebo; Inmazeb · For: Ebola Virus Disease
Sites: Kinshasa, Democratic Republic of the Congo; Conakry, Guinea; Monrovia, Liberia · 4 sites in all
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy VolunteersPivotal-lookingNot yet recruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05202288 · 132 participants (planned) · Start Jan 2027 · Primary completion Aug 2027
Drug: Ervebo; Inmazeb · For: Ebola Virus Disease
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02777151 · 24 participants · Start May 27, 2016 · Primary completion Apr 26, 2017
Drug: REGN3470-3471-3479; Placebo · For: Healthy Volunteers
Sites: Evansville, Indiana
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020.
Sivanandy P, Jun PH, Man LW, et al. · J Infect Public Health 2022 · Systematic Review
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.